1. Home /
  2. Biotechnology

Biotechnology

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results

Horizon Pharma's stock price skyrockets after the Dublin-based biotech reports positive results for a new drug to treat a rare but devastating eye disease.

Jim Cramer: My Best Stock Picks for Cannabis and China

Jim Cramer: My Best Stock Picks for Cannabis and China

And why I won't recommend any other stocks in these markets, right now.

Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition

Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition

Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

Acceleron Pharma Is Ready to Rally Ahead of Earnings

Acceleron Pharma Is Ready to Rally Ahead of Earnings

Here's how to trade XLRN stock right now.

China and Biotech Stocks Are Running Hot

China and Biotech Stocks Are Running Hot

If you are an index trader it is a tough call, but for stock-pickers it remains a very good trading market.

Clementia Pharmaceuticals Soars After Deal to Be Bought by France's Ipsen

Clementia Pharmaceuticals Soars After Deal to Be Bought by France's Ipsen

France's Ipsen agrees to buy Clementia Pharmaceuticals in a deal worth up to $1.31 billion.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'